EUVIMEDEUVIMED entdecken
Open Access

3D Printing as an Effective Quality Assurance Implementation in Massive-Scale SARS-CoV-2 Testing at a SwabSeq Next-Generation Sequencing Laboratory

Laila M Sathe, Nishrat N Khan, Jazmine M Williams, Rosita Saul, Kane Jajieh, Maryam R Sartippour, Rachel Young, Joanna Xie, Dawn M Marquette, Tiffany Duncan, Eleazar Eskin, Valerie A Arboleda iD

Laboratory Medicine · 2023

DOI: 10.1093/labmed/lmac161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laboratory Medicine, 2023. Verfasst von Laila M Sathe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, US. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Massive-scale SARS-CoV-2 testing using the SwabSeq diagnostic platform came with quality assurance challenges due to the novelty and scale of sequencing-based testing. The SwabSeq platform relies on accurate mapping between specimen identifiers and molecular barcodes to match a result back to a patient specimen. To identify and mitigate mapping errors, we instituted quality control using placement of negative controls within a rack of patient samples. We designed 2-dimensional paper templates to fit over a 96-position rack of specimens with holes to show the control tube placements. We designed and 3-dimensionally printed plastic templates that fit onto 4 racks of patient specimens and provide accurate indications of the correct control tube placements. The final plastic templates dramatically reduced plate mapping errors from 22.55% in January 2021 to less than 1% after implementation and training in January 2021. We show how 3D printing can be a cost-effective quality assurance tool to mitigate human error in the clinical laboratory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansCOVID-19 TestingHigh-Throughput Nucleotide SequencingPrinting, Three-DimensionalPlastics

Stichwörter der Autor:innen

3D printingSARS-CoV-2geneticsquality assurancesequencingvirology

Substanzen

Plastics

Autor:innen und Institutionen

  • Department of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, US.
  • UCLA SwabSeq COVID19 Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA, US.
  • Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, US.
  • Department of Pathology and Lab Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, US.

ORCID-Profile: Valerie A Arboleda

Zitieren

APA

Sathe, L. M., Khan, N. N., Williams, J. M., Saul, R., Jajieh, K., Sartippour, M. R., Young, R., Xie, J., Marquette, D. M., Duncan, T., Eskin, E., & Arboleda, V. A. (2023). 3D Printing as an Effective Quality Assurance Implementation in Massive-Scale SARS-CoV-2 Testing at a SwabSeq Next-Generation Sequencing Laboratory. Laboratory Medicine. https://doi.org/10.1093/labmed/lmac161

Vancouver

Sathe LM, Khan NN, Williams JM, Saul R, Jajieh K, Sartippour MR, et al. 3D Printing as an Effective Quality Assurance Implementation in Massive-Scale SARS-CoV-2 Testing at a SwabSeq Next-Generation Sequencing Laboratory. Laboratory Medicine. 2023. doi:10.1093/labmed/lmac161

BibTeX
@article{Sathe2023,
  author = {Sathe, Laila M and Khan, Nishrat N and Williams, Jazmine M and Saul, Rosita and Jajieh, Kane and Sartippour, Maryam R and Young, Rachel and Xie, Joanna and Marquette, Dawn M and Duncan, Tiffany and Eskin, Eleazar and Arboleda, Valerie A},
  title = {3D Printing as an Effective Quality Assurance Implementation in Massive-Scale SARS-CoV-2 Testing at a SwabSeq Next-Generation Sequencing Laboratory},
  journal = {Laboratory Medicine},
  year = {2023},
  doi = {10.1093/labmed/lmac161}
}
Kostenlos starten →